It’s been a challenging week for Canadian equities. The S&P/TSX Composite Index slipped by more than 200 points so far this week, as tech-sector weakness and concerns over an AI-driven bubble weighed on sentiment. Investors are grappling with uncertainty around consumer spending and valuation risks, even as inflation data remains relatively tame at 2.2 per cent. Given this narrative, staying informed about companies making strategic moves is more important than ever. Here are three stocks that deserve a closer look.
This article is a journalistic opinion piece which has been written based on independent research. It is intended to inform investors and should not be taken as a recommendation or financial advice.
MediPharm Labs (TSX:LABS, Forum), a pharmaceutical company specializing in precision-based cannabinoids, scored a major legal victory this week. The Ontario Superior Court of Justice dismissed a $50 million defamation claim brought by Apollo Technology Capital Corp., Nobul Technologies Inc., and Regan McGee against MediPharm’s CEO David Pidduck and Chairman Chris Taves. The court granted an anti-SLAPP motion, finding the plaintiffs failed to demonstrate “serious harm” and noting that the contested April 29 letter was “typical of a lawyer’s letter” in such circumstances.
What the “Buzz”
Our Bullboards have up to 2 million pageviews a day. Get the inside scoop on conversations around the most significant trends and stock appreciations in our weekly wrap up.
Get “Buzz on the Bullboards” delivered to your inbox every third Thursday!
Buzz on the Bullboards | Sign Up Here
This outcome removes a significant overhang from MediPharm’s governance narrative and reinforces management’s credibility. Coupled with strong Q3 results—17 per cent year-over-year revenue growth and disciplined cost management—the company appears well-positioned to continue its international expansion in medical cannabis markets. For investors, this legal clarity and operational momentum could signal upside potential in a sector still navigating regulatory complexity.
Oncolytics Biotech (NASDAQ:ONCY, Forum) announced a breakthrough alignment with the U.S. FDA on the design of its pivotal Phase 3 trial for pelareorep in first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC). This trial will evaluate pelareorep combined with standard chemotherapy—with or without a checkpoint inhibitor—against chemotherapy alone. The primary endpoint is overall survival, and the design includes flexibility for CPI selection, potentially accelerating timelines through interim analysis.
Why does this matter? Pancreatic cancer remains one of the most treatment-resistant malignancies, and immunotherapies have historically shown limited benefit. If successful, Oncolytics could deliver the first approved immunotherapy option for mPDAC, a milestone that would significantly expand its market opportunity. While the company faces cash burn challenges, analysts see substantial upside if pelareorep meets its endpoints, making ONCY a high-risk, high-reward play for biotech-focused investors.
Bombardier (TSX:BBD, Forum) is redefining luxury aviation with its announcement of an exclusive collaboration with ELIE SAAB, the Lebanese haute couture fashion house. The partnership will produce a bespoke cabin design for the upcoming Global 8000 aircraft, set for unveiling in 2026. This marks Bombardier’s first venture with a luxury fashion brand, aiming to merge cutting-edge engineering with world-class design for an unparalleled passenger experience.
The Global 8000 is already positioned as a flagship jet, boasting the longest range in its class (8,000 nautical miles) and a top speed of Mach 0.95, making it the fastest civilian aircraft since the Concorde. By adding ELIE SAAB’s signature aesthetic, Bombardier is targeting ultra-high-net-worth clients who demand exclusivity and elegance. For investors, this move underscores Bombardier’s strategy to differentiate in the premium segment—a potential catalyst for brand value and long-term growth.
Stay ahead of the curve. While the TSX has faced turbulence this week, these three companies demonstrate how strategic decisions—whether legal victories, regulatory milestones, or luxury partnerships—can create compelling narratives for investors. As markets remain volatile, deepening your due diligence on news-making stocks is essential to ensure your portfolio reflects both current opportunities and long-term trends. In times of uncertainty, informed investing isn’t just smart—it’s critical.
Get “Buzz on the Bullboards” delivered to your inbox every other Thursday!
Buzz on the Bullboards | Sign Up HereFor previous editions of Buzz on the Bullboards, click here.
Join the discussion: Find out what everybody’s saying about these stock on Stockhouse’s stock forums and message boards.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.